Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective randomized study compared with active control and placebo arms.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taejoon Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Male or female, age 20 or over

• Patient who have been diagnosed with dry eye syndrome at least 6 months ago

• Screening both eyes, the corrected visual acuity is 0.2 or more

• Written informed consent to participate in the trial

Exclusion Criteria:

• Screening visits within 2 months the patients with systemic or ocular disorders affected the test results (ocular surgery, trauma, or disease)

• Intraocular pressure(IOP)> 21 mmHg